BioSpace News Archive

Men of color in the United States are at an increased risk of prostate cancer and other prostate conditions, and despite advances in diagnosis and treatment, disparities still remain.

From life-saving cancer treatments to clean technologies that protect our environment, thousands of research staff in Canada are driving discoveries and innovations that support our well-being and our economy.

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that preclinical research on two of its drug candidates, uproleselan and GMI-1359, will be shared at the American Association for Cancer Research (AACR) Annual Meeting 2020, which will now be held virtually from June 22-24.

Beckman Coulter today announced it was awarded an expanded partnership with BARDA as part of their rapidly expanding COVID-19 medical countermeasure portfolio

For the fourth consecutive year, Blue Cross Blue Shield of Massachusetts was named the top health plan in Massachusetts for member satisfaction by J.D. Power, a global expert in customer insights.

California Life Sciences Institute on Friday named American High School 11th grader Shreya Ramachandran the winner of CLSI’s 2020 Bay Area BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research and innovation in the biotechnology field.

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that Dr. Moncef Slaoui has resigned from Moderna’s Board of Directors upon appointment of his new role to oversee the White House’s Operation Warp Speed initiative.

Aesculap Inc., in partnership with The Christoph Miethke GmbH & Co. KG (MIETHKE), is pleased to announce the launch of the M.blue valve, the latest generation of Hydrocephalus valve technology

Lifestyle choices continue to be a leading risk factor for a wide array of health conditions, including lowered hormone levels and subsequent sequalae.

Asset Acquisition of new Ophthalmic Viscoelastic Device (OVD) Portfolio from Croma® Pharma GmbH (Croma) of Austria